Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
183 shown of 6,817 total abstracts
  1. Abstract 47762026-06-04 · 20:30 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in gastric
    H. Borghaei, S. Antonia, N. Rizvi · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  2. Abstract 19612026-06-04 · 18:30 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    A. Spira, C. Robert, R. Herbst · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 12952026-06-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-694 study)
    J. Brahmer, F. Andre, E. Winer, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 43532026-06-04 · 20:00 CT · S100A
    ASCENT-46: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    J. Brahmer, F. Andre, C. Robert, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 42192026-06-05 · 20:30 CT · S406
    EV-105: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    H. Rugo, S. Modi, E. Winer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  6. Abstract 48502026-06-05 · 21:15 CT · Hall B1
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    F. Andre, E. Winer, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  7. Abstract 19172026-06-04 · 18:30 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-374
    M. Reck, A. Spira, S. Modi, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 11112026-06-05 · 20:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-198
    M. Reck, S. Tolaney, S. Modi · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 98352026-06-03 · 14:45 CT · S100A
    Quality of life outcomes with Keytruda in patients with NSCLC
    A. Spira, L. Paz-Ares, P. Schmid, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  10. Abstract 46962026-06-03 · 21:45 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    T. Mok, R. Herbst, S. Modi, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  11. Abstract 16612026-06-01 · 21:45 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    A. Spira, J. Brahmer, R. Herbst, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 48632026-06-01 · 21:45 CT · S100A
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    S. Antonia, F. Andre, S. Modi · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  13. Abstract 98662026-06-05 · 16:30 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-222
    S. Antonia, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 14682026-06-03 · 15:30 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-163
    H. Borghaei, C. Saura, N. Rizvi, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 60572026-06-04 · 21:30 CT · Arie Crown Theater
    KEYNOTE-81: Keytruda (pembrolizumab) 3L+ in RCC
    S. Peters, J. Brahmer, M. Reck, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  16. Abstract 90122026-06-01 · 21:00 CT · S100A
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    P. Schmid, J. Cortes, T. Mok · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 45752026-06-02 · 14:00 CT · Hall B1
    ASCENT-329: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    S. Peters, M.C. Garassino, M. Reck, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  18. Abstract 96382026-06-05 · 16:15 CT · Arie Crown Theater
    KEYNOTE-17: Keytruda (pembrolizumab) 2L in NSCLC
    T. Mok, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract 64862026-06-05 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-248 study)
    M. Krop, J. Brahmer · Mayo Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  20. Abstract 93192026-06-03 · 13:30 CT · S406
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-294
    G. Curigliano, E. Winer · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  21. Abstract 16772026-06-01 · 14:15 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-998 study)
    G. Curigliano, S. Tolaney · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 16332026-06-05 · 19:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-912
    E. Winer, A. Spira, M.C. Garassino, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 17172026-06-02 · 16:15 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    S. Antonia, M.C. Garassino, A. Spira, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 98312026-06-04 · 20:15 CT · Arie Crown Theater
    FLAURA-840: Tagrisso (osimertinib) adjuvant in NSCLC
    P. Schmid, A. Spira, S. Peters, et al. · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 17482026-06-04 · 20:00 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-445
    J. Cortes, A. Spira, H. Borghaei, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 95422026-06-04 · 21:30 CT · S100A
    Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-286
    J. Brahmer, A. Spira, P. Schmid, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 91812026-06-05 · 14:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-469
    J. Brahmer, T. Mok, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 65662026-06-03 · 13:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in RCC
    L. Paz-Ares, S. Peters, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  29. Abstract 46462026-06-05 · 14:30 CT · Arie Crown Theater
    EV-591: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    A. Spira, F. Andre · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  30. Abstract 55252026-06-01 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-84 study)
    P. Schmid, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  31. Abstract 11232026-06-05 · 16:00 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-623 study)
    M.C. Garassino, R. Herbst, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 69432026-06-05 · 13:30 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-597 study)
    M. Reck, H. Rugo, S. Modi, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  33. Abstract 68222026-06-02 · 16:00 CT · S100A
    CheckMate-686: Opdivo (nivolumab) neoadjuvant in RCC
    S. Tolaney, H. Borghaei · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  34. Abstract 18052026-06-04 · 16:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-297
    P. Schmid, F. Andre, T. Mok, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 93422026-06-01 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-143
    E. Winer, N. Rizvi, F. Andre · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 12682026-06-01 · 14:15 CT · Hall B1
    MONALEESA-277: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    J. Cortes, T. Mok, S. Antonia, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 95132026-06-02 · 16:15 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    C. Saura, A. Spira, J. Cortes, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  38. Abstract 95362026-06-01 · 16:45 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-419
    C. Saura, L. Paz-Ares, N. Rizvi, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 10932026-06-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-79 study)
    J. Brahmer, J. Cortes, M. Krop · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 15382026-06-05 · 20:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-644 study)
    H. Borghaei, G. Curigliano, M. Reck, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 19292026-06-02 · 13:30 CT · E450
    MONARCH-916: Verzenio (abemaciclib) 1L in HR+ breast cancer
    F. Andre, M.C. Garassino, S. Modi, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 48822026-06-02 · 19:00 CT · E450
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    C. Robert, P. Schmid, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  43. Abstract 17952026-06-02 · 14:45 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    L. Paz-Ares, J. Brahmer, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 15012026-06-02 · 21:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-221
    L. Paz-Ares, M. Krop, M. Reck, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 13922026-06-02 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-371 study)
    G. Curigliano, J. Cortes, H. Borghaei, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 57502026-06-02 · 21:45 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-38
    M.C. Garassino, S. Peters, M. Reck, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  47. Abstract 61352026-06-04 · 14:15 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    H. Borghaei, P. Schmid, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  48. Abstract 51922026-06-03 · 18:15 CT · Arie Crown Theater
    OlympiA-620: Lynparza (olaparib) adjuvant in prostate
    H. Borghaei, P. Schmid, S. Antonia, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  49. Abstract 93702026-06-02 · 14:00 CT · S100A
    FLAURA-403: Tagrisso (osimertinib) maintenance in NSCLC
    R. Herbst, H. Borghaei, M. Reck · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 97172026-06-02 · 21:00 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for NSCLC: PACIFIC-781
    E. Winer, M. Reck · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  51. Abstract 90722026-06-02 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with NSCLC
    E. Winer, S. Tolaney, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 44972026-06-03 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-46 study)
    S. Tolaney, S. Peters · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  53. Abstract 17092026-06-05 · 16:15 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-173
    C. Robert, C. Saura, S. Tolaney, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 16262026-06-04 · 13:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-137 study)
    S. Modi, M.C. Garassino · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 15622026-06-03 · 19:00 CT · S406
    Quality of life outcomes with Keytruda in patients with TNBC
    C. Saura, H. Borghaei, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 46772026-06-01 · 14:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-2 study)
    H. Borghaei, G. Curigliano, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  57. Abstract 12142026-06-03 · 14:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-867 study)
    J. Cortes, R. Herbst, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 56032026-06-02 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 3L+ for ovarian: OlympiA-981
    H. Borghaei, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  59. Abstract 10002026-06-05 · 18:45 CT · E450
    KEYNOTE-277: Keytruda (pembrolizumab) 2L in TNBC
    S. Peters, H. Borghaei, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 15062026-06-04 · 20:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-380
    P. Schmid, M. Reck, T. Mok · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 12802026-06-01 · 20:45 CT · S406
    MONARCH-219: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    J. Brahmer, M.C. Garassino, F. Andre · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 43122026-06-01 · 14:30 CT · S406
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-123
    S. Tolaney, F. Andre, G. Curigliano · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  63. Abstract 61442026-06-03 · 21:45 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-856
    J. Brahmer, C. Saura, G. Curigliano, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  64. Abstract 19922026-06-02 · 20:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-536
    S. Antonia, C. Robert, H. Borghaei, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 15902026-06-04 · 20:00 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-727
    J. Brahmer, M. Reck, C. Robert, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 18692026-06-03 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-781
    J. Cortes, M. Krop · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 95062026-06-01 · 14:45 CT · S406
    Quality of life outcomes with Tagrisso in patients with NSCLC
    H. Rugo, C. Robert, S. Peters · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  68. Abstract 12332026-06-01 · 21:00 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    F. Andre, P. Schmid, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 48212026-06-03 · 13:30 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-144
    N. Rizvi, C. Robert, S. Tolaney, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  70. Abstract 49812026-06-04 · 16:45 CT · S100A
    ASCENT-377: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    E. Winer, S. Peters, H. Rugo, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  71. Abstract 95592026-06-01 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with NSCLC
    H. Rugo, M.C. Garassino, A. Spira · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  72. Abstract 90562026-06-03 · 21:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-244 study)
    P. Schmid, C. Robert, S. Tolaney · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  73. Abstract 12792026-06-04 · 18:45 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    E. Winer, H. Borghaei, F. Andre · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 42102026-06-01 · 20:30 CT · S100A
    Long-term follow-up of Opdivo maintenance for HCC: CheckMate-154
    S. Tolaney, M. Krop, P. Schmid, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  75. Abstract 92002026-06-04 · 19:30 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-210
    S. Antonia, F. Andre, R. Herbst · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  76. Abstract 45762026-06-04 · 13:15 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-590
    J. Brahmer, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  77. Abstract 40052026-06-02 · 15:00 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    M. Reck, M. Krop, E. Winer, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  78. Abstract 17562026-06-05 · 19:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-219
    J. Brahmer, H. Borghaei, N. Rizvi · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 90112026-06-04 · 18:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-377 study)
    G. Curigliano, M. Reck, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  80. Abstract 56262026-06-02 · 18:15 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with prostate
    S. Modi, C. Saura, S. Tolaney · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  81. Abstract 12632026-06-03 · 20:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-283
    N. Rizvi, C. Saura · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  82. Abstract 92492026-06-02 · 16:00 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    E. Winer, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  83. Abstract 13112026-06-02 · 18:45 CT · Arie Crown Theater
    PALOMA-86: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, R. Herbst · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 40032026-06-01 · 18:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-151 study)
    T. Mok, A. Spira, L. Paz-Ares, et al. · University of Chicago
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  85. Abstract 17482026-06-04 · 21:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-904
    G. Curigliano, J. Cortes, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  86. Abstract 99402026-06-05 · 19:15 CT · S406
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-924
    M. Reck, M. Krop · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  87. Abstract 17182026-06-02 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-404 study)
    J. Cortes, M. Krop, M. Reck, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 12062026-06-04 · 19:15 CT · Hall B1
    MONARCH-410: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    H. Rugo, H. Borghaei, C. Saura, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 13442026-06-02 · 13:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-248
    J. Cortes, S. Peters, J. Brahmer, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  90. Abstract 43772026-06-03 · 21:30 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    H. Borghaei, N. Rizvi, G. Curigliano · National Cancer Center Japan
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  91. Abstract 15282026-06-03 · 16:00 CT · S100A
    DESTINY-Breast-29: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    N. Rizvi, A. Spira, H. Borghaei, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  92. Abstract 41632026-06-05 · 14:30 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with gastric
    E. Winer, T. Mok, M. Krop · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  93. Abstract 16392026-06-04 · 18:15 CT · S100A
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-42
    E. Winer, H. Rugo, N. Rizvi, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  94. Abstract 45032026-06-03 · 18:45 CT · S406
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-379
    J. Brahmer, C. Saura · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  95. Abstract 12732026-06-04 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-99 study)
    N. Rizvi, H. Borghaei, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 98412026-06-03 · 15:15 CT · Hall B1
    IMpower-416: Tecentriq (atezolizumab) 3L+ in NSCLC
    G. Curigliano, M. Reck · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  97. Abstract 13522026-06-01 · 21:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-992
    A. Spira, C. Robert · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  98. Abstract 40382026-06-05 · 18:00 CT · S100A
    EV-432: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    R. Herbst, M. Reck, S. Antonia, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  99. Abstract 14752026-06-05 · 20:00 CT · Hall B1
    MONARCH-25: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    E. Winer, S. Modi, L. Paz-Ares · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  100. Abstract 18282026-06-02 · 14:15 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    N. Rizvi, S. Antonia, E. Winer, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 64052026-06-05 · 19:15 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-616 study)
    J. Brahmer, J. Cortes, S. Peters, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  102. Abstract 94712026-06-05 · 14:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-753
    T. Mok, S. Peters, M. Krop, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  103. Abstract 11372026-06-02 · 16:00 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    R. Herbst, F. Andre, C. Saura · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 91252026-06-02 · 19:30 CT · Hall B1
    PACIFIC-487: Imfinzi (durvalumab) 1L in NSCLC
    E. Winer, S. Tolaney, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  105. Abstract 94582026-06-05 · 15:00 CT · E450
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-830
    H. Rugo, R. Herbst · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  106. Abstract 101222026-06-02 · 19:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    M. Reck, R. Herbst · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  107. Abstract 15242026-06-02 · 16:30 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    F. Andre, S. Peters · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 40862026-06-02 · 16:00 CT · S100A
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-922 study)
    T. Mok, E. Winer · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  109. Abstract 43952026-06-04 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-643 study)
    M. Krop, M. Reck, R. Herbst, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  110. Abstract 49602026-06-01 · 16:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with HCC
    T. Mok, S. Peters, G. Curigliano, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  111. Abstract 98562026-06-05 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-261
    G. Curigliano, E. Winer · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  112. Abstract 102192026-06-04 · 19:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-360
    H. Borghaei, M. Reck, A. Spira · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  113. Abstract 17782026-06-04 · 19:45 CT · E450
    MONALEESA-137: Kisqali (ribociclib) 2L in HR+ breast cancer
    H. Borghaei, J. Cortes · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 59112026-06-05 · 15:00 CT · Arie Crown Theater
    OlympiA-208: Lynparza (olaparib) adjuvant in prostate
    E. Winer, A. Spira, H. Borghaei · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  115. Abstract 91642026-06-05 · 14:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-214 study)
    C. Saura, J. Brahmer · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  116. Abstract 17412026-06-04 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-287 study)
    J. Cortes, H. Rugo · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 10202026-06-01 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-808
    R. Herbst, A. Spira, C. Saura, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 104582026-06-04 · 16:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    A. Spira, E. Winer, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  119. Abstract 17052026-06-02 · 16:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-679 study)
    F. Andre, M. Reck, H. Rugo, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 95652026-06-02 · 21:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-230
    L. Paz-Ares, M. Reck, H. Rugo · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  121. Abstract 16952026-06-03 · 16:00 CT · Hall B1
    MONARCH-142: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M.C. Garassino, J. Cortes, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 44362026-06-01 · 21:30 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-132
    S. Modi, F. Andre, S. Antonia · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  123. Abstract 56882026-06-01 · 18:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in ovarian (the OlympiA-458 study)
    L. Paz-Ares, S. Peters, H. Borghaei, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  124. Abstract 96712026-06-03 · 15:00 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-399
    S. Peters, J. Brahmer, L. Paz-Ares, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  125. Abstract 43092026-06-05 · 13:15 CT · Hall B1
    IMpower-646: Tecentriq (atezolizumab) neoadjuvant in HCC
    R. Herbst, M. Reck, J. Brahmer, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  126. Abstract 12992026-06-05 · 19:00 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    R. Herbst, S. Antonia, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  127. Abstract 45952026-06-05 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Imfinzi in patients with biliary tract
    L. Paz-Ares, S. Modi, H. Rugo · Royal Marsden Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  128. Abstract 19042026-06-01 · 16:15 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    M.C. Garassino, H. Rugo · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 12762026-06-05 · 21:15 CT · Hall B1
    PALOMA-649: Ibrance (palbociclib) 2L in HR+ breast cancer
    H. Borghaei, C. Robert, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 19632026-06-04 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-164 study)
    S. Modi, M. Reck, A. Spira · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  131. Abstract 10582026-06-01 · 13:00 CT · S406
    OlympiA-935: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    J. Cortes, M. Reck, T. Mok, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  132. Abstract 98172026-06-03 · 18:00 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-275
    S. Tolaney, R. Herbst, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  133. Abstract 104522026-06-02 · 19:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-38 study)
    M.C. Garassino, L. Paz-Ares, M. Reck · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  134. Abstract 95032026-06-02 · 18:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-368 study)
    J. Brahmer, P. Schmid, N. Rizvi · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  135. Abstract 90772026-06-03 · 16:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with SCLC
    M. Krop, S. Antonia, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  136. Abstract 95932026-06-03 · 18:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-991
    J. Brahmer, N. Rizvi, A. Spira, et al. · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  137. Abstract 99532026-06-02 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Peters, J. Cortes, C. Saura, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  138. Abstract 49282026-06-05 · 21:45 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in HCC
    P. Schmid, C. Saura, M. Krop · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  139. Abstract 98312026-06-02 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-258 study)
    M. Reck, T. Mok · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  140. Abstract 19342026-06-01 · 21:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-350 study)
    S. Tolaney, C. Saura, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 10582026-06-02 · 14:15 CT · E450
    MONALEESA-636: Kisqali (ribociclib) 2L in HR+ breast cancer
    P. Schmid, M. Krop, H. Rugo, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 97012026-06-02 · 14:30 CT · Arie Crown Theater
    DESTINY-Breast-392: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    L. Paz-Ares, H. Borghaei, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  143. Abstract 49622026-06-02 · 20:45 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for HCC: CheckMate-902
    M. Krop, N. Rizvi, F. Andre, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  144. Abstract 19202026-06-05 · 20:00 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-85
    L. Paz-Ares, H. Rugo, H. Borghaei, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 96112026-06-05 · 21:15 CT · S406
    FLAURA-916: Tagrisso (osimertinib) neoadjuvant in NSCLC
    N. Rizvi, R. Herbst · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  146. Abstract 11672026-06-02 · 21:00 CT · Hall B1
    ASCENT-207: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    C. Saura, F. Andre · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 10832026-06-03 · 19:45 CT · S100A
    DESTINY-Breast-615: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    M. Krop, M.C. Garassino, J. Brahmer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 40502026-06-04 · 19:30 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-424
    J. Cortes, H. Borghaei, L. Paz-Ares, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  149. Abstract 99562026-06-05 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-26 study)
    P. Schmid, C. Robert, H. Borghaei, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  150. Abstract 98422026-06-01 · 13:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-725
    L. Paz-Ares, C. Robert, S. Peters · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  151. Abstract 96752026-06-04 · 14:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-150 study)
    M.C. Garassino, J. Cortes, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  152. Abstract 51712026-06-04 · 14:30 CT · Arie Crown Theater
    OlympiA-492: Lynparza (olaparib) 3L+ in prostate
    S. Antonia, J. Brahmer, P. Schmid · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  153. Abstract 16622026-06-05 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-550 study)
    J. Cortes, J. Brahmer, A. Spira, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 99272026-06-03 · 13:15 CT · Arie Crown Theater
    FLAURA-856: Tagrisso (osimertinib) maintenance in NSCLC
    C. Saura, J. Brahmer, N. Rizvi, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  155. Abstract 102812026-06-04 · 13:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-751 study)
    C. Saura, M.C. Garassino, E. Winer · Chinese University of Hong Kong
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  156. Abstract 48122026-06-05 · 14:00 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for HCC: CheckMate-723
    M.C. Garassino, H. Rugo, S. Tolaney · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  157. Abstract 16562026-06-02 · 20:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-146
    M. Krop, S. Antonia, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  158. Abstract 17372026-06-05 · 18:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-381
    M. Reck, J. Cortes · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 63352026-06-04 · 21:15 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-618
    L. Paz-Ares, J. Cortes, S. Antonia, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  160. Abstract 96462026-06-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-7 study)
    J. Brahmer, E. Winer, L. Paz-Ares · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  161. Abstract 10972026-06-01 · 19:45 CT · Arie Crown Theater
    OlympiA-824: Lynparza (olaparib) adjuvant in HR+ breast cancer
    C. Saura, S. Peters, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  162. Abstract 90632026-06-03 · 20:00 CT · Arie Crown Theater
    CheckMate-173: Opdivo (nivolumab) maintenance in NSCLC
    S. Modi, J. Brahmer, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  163. Abstract 16352026-06-04 · 19:00 CT · Arie Crown Theater
    MONARCH-56: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Antonia, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  164. Abstract 92772026-06-05 · 21:30 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-888 study)
    H. Borghaei, S. Antonia, P. Schmid · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  165. Abstract 45812026-06-03 · 13:15 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-757 study)
    J. Brahmer, P. Schmid, G. Curigliano, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  166. Abstract 13542026-06-05 · 13:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-655
    C. Saura, N. Rizvi · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  167. Abstract 99442026-06-03 · 15:15 CT · Hall B1
    CheckMate-658: Opdivo (nivolumab) 1L in metastatic melanoma
    G. Curigliano, N. Rizvi, S. Peters, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  168. Abstract 98862026-06-04 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-964
    J. Brahmer, S. Tolaney · Royal Marsden Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  169. Abstract 12682026-06-03 · 18:45 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    A. Spira, C. Saura, N. Rizvi · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  170. Abstract 91442026-06-01 · 13:00 CT · Arie Crown Theater
    FLAURA-572: Tagrisso (osimertinib) 2L in NSCLC
    G. Curigliano, N. Rizvi, F. Andre, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  171. Abstract 95992026-06-01 · 16:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-208
    T. Mok, G. Curigliano, S. Modi, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  172. Abstract 46772026-06-04 · 19:15 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-489
    G. Curigliano, S. Antonia, T. Mok, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  173. Abstract 97802026-06-02 · 15:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-707
    R. Herbst, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  174. Abstract 96862026-06-04 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-169
    M. Krop, S. Modi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  175. Abstract 98612026-06-05 · 14:15 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-717
    L. Paz-Ares, T. Mok · National Cancer Center Japan
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  176. Abstract 95702026-06-03 · 14:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-109 study)
    G. Curigliano, S. Tolaney, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  177. Abstract 96722026-06-04 · 16:45 CT · Hall B1
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-55
    C. Saura, S. Peters, F. Andre · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  178. Abstract 16092026-06-02 · 21:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-705 study)
    E. Winer, S. Tolaney, R. Herbst · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  179. Abstract 94342026-06-03 · 21:15 CT · S406
    PACIFIC-6: Imfinzi (durvalumab) 3L+ in SCLC
    H. Borghaei, M. Reck, E. Winer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  180. Abstract 44652026-06-02 · 14:00 CT · E450
    CheckMate-704: Opdivo (nivolumab) 1L in HCC
    S. Peters, F. Andre, S. Modi, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  181. Abstract 12472026-06-03 · 13:30 CT · Hall B1
    MONALEESA-331: Kisqali (ribociclib) 1L in HR+ breast cancer
    S. Antonia, H. Borghaei · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  182. Abstract 93422026-06-03 · 21:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-998
    R. Herbst, T. Mok, E. Winer, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  183. Abstract 95922026-06-01 · 14:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-71
    S. Antonia, F. Andre · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.